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PTHrP-related Hypercalcaemia in Infancy and
Congenital Anomalies of the Kidney and Urinary
Tract (CAKUT)
Nardeen Kodous1, Guido Filler1*, Ajay Parkash Sharma1 and Tamara Angela Van Hooren2
Abstract
Background: Severe hypercalcaemia is a rare but clinically significant condition in infancy and childhood.
Parathyroid hormone-related peptide (PTHrP)-mediated hypercalcaemia resulting from a malignancy is rare and only
a handful of case reports have outlined its incidence alongside a benign condition.
Objectives: To describe the diagnostic workup and management of an infant with hypercalcaemia, renal dysplasia,
and elevated PTHrP levels.
Design: Case report.
Setting: The Victoria Hospital campus of the London Health Sciences Centre in London, Ontario, Canada.
Patients: A child with congenital anomalies of the kidneys and urinary tract (CAKUT), stage 2 chronic kidney
disease (CKD), and renal dysplasia who presented with severe hypercalcaemia.
Measurements: Weight, renal ultrasound, creatinine, cystatin C, eGFR, calcium, urea, bicarbonate, serum sodium,
fractional sodium excretion, urine calcium to creatinine ratio, PTH, TSH, Free T4, AM cortisol, HMA, VMA, 25-vitamin
D, 1,25 dihydroxy-vitamin D, calcitriol, vitamin A, ACE levels, skull and chest x-rays, alkaline phosphatase, CBC,
tumour lysis profile, catecholamine breakdown, whole-body MRI, PTHrP.
Methods: Full diagnostic workup and patient management. Patient treated with intravenous hydration, furosemide,
calcitonin and CalciLo.
Results: PTHrP was elevated and no evidence of a malignancy was found. Treatment consisting of a low-calcium
CalciLo diet (in place of breast milk) adequately controlled the patient’s hypercalcaemia. Hypercalcaemia associated
with CAKUT in infancy is not all that uncommon and was reported in 15/99 infants in another study, most of whom
had a suppressed PTH similar to that of our patient. PTHrP was not measured in these cases and may have also
been elevated.
Limitations: The study is limited in that it is a description of a single patient case. Future measurement of PTHrP in
similar patients is necessary to confirm our results.
Conclusions: The possibility of elevated PTHrP levels must be considered in patients with known renal dysplasia
who are differentially diagnosed with hypercalcaemia.
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Abrégé
Contexte: L’hypercalcémie aigue est rare, bien qu’elle constitue un trouble important de la petite enfance et de
l’enfance du point de vue clinique. Rares sont les hypercalcémies à médiation de peptide lié à l’hormone
parathyroïdienne (PTHrP) qui résultent d’une malignité, et seules quelques observations cliniques témoignent de
leur incidence dans les cas de troubles bénins.
Objectifs: Décrire le bilan diagnostic et la prise en charge d’un petit enfant atteint d’hypercalcémie, de dysplasie
rénale, et présentant des taux élevés de PTHrP.
Type d’étude: Observation clinique.
Contexte: Le campus de l’Hôpital Victoria du Centre de services de santé de London (London Health Sciences
Centre), à London, en Ontario, au Canada.
Participants: Un enfant atteint d’anomalies congénitales du rein et des voies urinaires (CAKUT), d’insuffisance
rénale chronique (IRC) de stade 2 et de dysplasie rénale, qui présentait une hypercalcémie aigue.
Mesures: Le poids, l’échographie rénale, la créatinine, la cystatine C, le R-EGF, le calcium, l’urée, le bicarbonate,
le sodium sérique, la fraction d’excrétion du sodium, le ratio calcium/créatine dans l’urine, la PTH, la TSH, le T4 libre,
le taux de cortisol le matin, l’acide homomandelique, l’acide vanillylmandelique , le 25-vitamine D, le 1,25
dihydroxy-vitamine D, le calcitriol, la vitamineA, les taux d’enzyme de conversion de l’angiotensine, les radiographies
thoraciques et crâniennes, la phosphatase alcaline, la formule sanguine complète, le profil de lyse tumorale, les taux de
catécholamine, la résonnance magnétique du corps entier, le taux de PTHrP
Méthodes: Bilan diagnostic et prise en charge du patient. Le patient a reçu une hydratation intraveineuse, du
furosémide, de la calcitonine et du Calcilo.
Résultats: Le taux de PTHrP était élevé et on n’a découvert aucune trace d’une malignité. Le traitement, qui consistait
en un régime faible en calcium de Calcilo (en remplacement du lait maternel), a permis de limiter adéquatement
l’hypercalcémie du patient. L’hypercalcémie associée à des anomalies congénitales du rein et des voies urinaires dans la
petite enfance n’est pas si rare. Une autre étude a fait état de 15/99 petits enfants, dont la plupart présentait un faible
taux de PTH semblable à celui de notre patient. Le PTHrP, qui n’a pas été mesuré dans ces cas, pourrait également
avoir été élevé.
Limites de l’étude: L’étude est limitée en ceci qu’elle consiste en la description d’un seul cas. Des mesures du taux de
PTHrP chez des patients similaires seront nécessaires pour confirmer nos résultats.
Conclusions: L’éventualité de taux élevés de PTHrP doit être envisagée chez les patients atteints de dysplasie rénale et
chez lesquels on a autrement diagnostiqué une hypercalcémie.
What was known before
Hypercalcaemia, while otherwise rare in infants, is some-
times seen in infants with congenital anomalies of the kid-
neys and the urinary tract (CAKUT). Only a small fraction
of these patients have signs of a vitamin D overdose.
What this adds
Our case report suggests that hypercalcaemia may result
from the overproduction of PTHrP in patients with
CAKUT and adequately suppressed PTH. Our case also
suggests alternative approaches to maintain normocal-
caemia with hydration, furosemide, and calcitonin, ra-
ther than bisphosphonate.
Background
Severe hypercalcaemia is a rare but clinically significant
condition in infancy and childhood. Symptoms and com-
plications may include stomach upset, nausea, vomiting
and constipation, confusion, lethargy and fatigue, and
calcification of the kidney with subsequent dehydration
and excessive thirst. The differential diagnosis for hyper-
calcaemia in infancy and childhood includes: parathyroid
hormone (PTH)-dependent anomalies, including MEN
syndromes I and II and Jansen’s metaphyseal chondro-
dysplasia; calcium-sensing receptor disorders such as
with severe neonatal hyperparathyroidism or familial
hypocalciuric hypercalcaemia (a rare genetic disorder);
vitamin D-related anomalies including vitamin D intoxi-
cation, Williams syndrome, and granulomatous diseases;
and disorders related to vitamin A intoxication or
immobilization (Figure 1) [1]. Hypercalcaemia may also
be the product of a malignancy, often mediated by para-
thyroid hormone-related protein (PTHrP) [2,3]. PTHrP
is homologous in structure to PTH. It works both in a
paracrine and autocrine fashion and can be found in epi-
thelial and mesenchymal tissues, endocrine glands, and
the central nervous system [4]. Although rare, benign tu-
mours can also secrete PTHrP [5-7]. This phenomenon
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was recently reported in benign mesoblastic nephroma
[8]. Grob et al. provided another example with their re-
cent report of PTHrP-related hypercalcaemia in an in-
fant with renal dysplasia in the absence of a tumour [9].
Here we report another case of hypercalcaemia associ-
ated with elevated PTHrP levels in the context of known
renal dysplasia in an infant. Diagnostic workup and
management are discussed. Explicit written consent for
this case report was obtained.
Case report
A 5-month-old Caucasian female infant with congenital
anomalies of the kidneys and urinary tract (CAKUT)
presented to our centre with a history of emesis,
decreased oral intake, and lethargy. She had been born
at 40 weeks and 4 days after an uncomplicated preg-
nancy with a birth weight of 4010 grams to unrelated
parents. In a previous examination, she was found to
have bilateral renal duplication and bilateral ureteroceles
corresponding to the upper moieties, with grade 5
vesicoureteric reflux in both lower moieties. The ureter-
oceles were managed with bilateral ureterocele incisions.
A renal ultrasound found normally sized (6 cm long)
kidneys with bilateral renal duplication, bilateral tortu-
ous hydroureter, and thin renal cortex with increased
cortical echogenicity and small cysts (Figure 2). Her
serum creatinine peaked at 117 μmol/L after birth. At
3 months of age, her cystatin C-estimated glomular fil-
tration rate (eGFR) [10,11] was 51 mL/min/1.73 m2 and
at 5 months it rose to 64 mL/min/1.73 m2, indicating
stage 2 chronic kidney disease (CKD). The patient was
not on any medication at the time of admission. Her
weight dropped from 5180 grams at admission to 4890
grams one week later, a loss of 6%. On examination, she
exhibited signs of dehydration with sunken fontanels
and dry mucous membranes. She was afebrile. Blood
work showed a calcium level of 4.98 mmol/L (reference
interval (RI) 2.24-2.74 mmol/L), phosphate 0.83 mmol/L
(RI 1.30 to 2.60 mmol/L), creatinine 63 μmol/L (RI < 53
umol/L), urea 13.7 mmol/L (RI < 7.0 mmol/L) and bicar-
bonate 15 mmol/L (RI 22–29 mmol/L). Her serum so-
dium was 134 mmol/L and her fractional sodium
excretion was 20.06%, suggesting some sodium wasting,
which is frequently seen in patients with renal dysplasia.
Figure 1 Diagnostic and treatment algorithm for hypercalcaemia in neonates and infants (adapted from Lietman et al. [1]).
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Diagnostic work-up
An extensive investigation was undertaken to determine
the aetiology of this child’s hypercalcaemia. Urine testing
showed significant hypercalciuria with elevated Uca/cr ra-
tios of up to 9.8 (normal <0.6) mmol/mmol. A renal ultra-
sound showed multiple echogenic structures in both
kidneys and bilateral calcifications of the renal pyramids
(Figure 1). PTH was adequately suppressed at 0.4 (normal
1.6-6.9) pmol/L, thereby ruling out primary hyperpara-
thyroidism. Secondary and tertiary hyperparathyroidism
were highly unlikely in view of the mild decrease in GFR
(CKD 2). TSH, Free T4, and AM cortisol were normal,
ruling out hyperthyroidism and adrenal insufficiency.
There was no clinical evidence of acromegaly. Pheochro-
mocytoma was ruled out given that the patient was
normotensive, and HMA and VMA levels were normal.
The patient’s 25-vitamin D level was normal at 140 pmol/
L (RI 75 to 225 nmol/L), while her 1,25 dihydroxy-vitamin
D level was unexpectedly low at 10 pmol/L, ruling out
Vitamin D excess. Vitamin A levels were low, also ruling
out vitamin A intoxication. Normal or low ACE levels in-
dicated that sarcoidosis was unlikely. A normal chest x-ray
revealed no radiological evidence of tuberculosis. Finally,
the patient had low calcitriol levels were low, which is
inconsistent with granulomatous disease. Given that the
infant’s calcium levels had previously been normal and she
did not have a family history of familial hypocalciuric
hypercalcaemia this was an unlikely diagnosis. The patient
was not on any medications known to cause hypercalcae-
mia. There was also no evidence of rhabdomyolysis. Bone
lysis and immobilization-related high bone turnover was
ruled out with the patient’s normal alkaline phosphatase
results and skull and chest x-rays negative, which were
negative for bony changes. Given that all other potential
causes for hypercalcaemia had been ruled out, our haema-
tology oncology colleagues were consulted to rule out
malignancy-related humoral hypercalcaemia. A normal
CBC and tumour lysis profile ruled out leukemia, the most
common cause of malignancy-related hypercalcaemia in
this age group. There was no clinical or radiological
evidence of lymphoma and normal urine levels of cat-
echolamine breakdown products ruled out neuroblastoma.
An ultrasound showed no hepatosplenomegaly, and a
whole-body MRI revealed no radiological evidence of ma-
lignancy. Malignancy-related humoral hypercalcaemia was
therefore an unlikely aetiology. The patient’s PTHrP level
was, however, found to be elevated at 3.8 (normal <2,
Mayo Medical Laboratories) pmol/L [8], and phosphate
wasting (TmP/GFR was 0.59, reference range for this age
1.15-2.60) [12] suggested PTHrP-related hypercalcaemia.
Treatment
Initial treatment consisted of aggressive rehydration with
intravenous fluids (Ringers lactate, 20 mL/kg, repeated
three times). Her calcium levels did not initially respond,
and she was given intravenous furosemide (1 mg/kg
intravenously, possible up to 10 mg/kg/day) and calci-
tonin (initially 2 units/kg subcutaneously, then 4 units/
kg/day every 24 hours, could be given every 12 hours)
with good effect (serum calcium dropped to 2.14 mmol/
L in 48 hours). Her calcium levels remained stable with
all interventions withdrawn for several days prior to her
discharge. Her calcium level at time of discharge was
2.12 mmol/L. Unfortunately, she was readmitted for
recurrent hypercalcaemia one month after her initial dis-
charge with a calcium level of 4.37 mmol/L. She was
Figure 2 Representative section of the right kidney showing multiple echoic structures in the calices without shadowing.
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once again treated with intravenous fluids, Lasix, and
calcitonin again. Her calcium level at time of discharge
was 2.44 mmol/L (Figure 3). A further one month later,
outpatient laboratory testing revealed an elevated cal-
cium level of 3.0 mmol/L, prompting the introduction of
CalciLo (a low-calcium, vitamin D-free infant formula
that contains 1/10th the calcium concentration of breast
milk). CalciLo was discontinued 6 months later, and her
calcium levels have remained stable after 6 months of
follow-up visits. Table 1 provides the laboratory findings
at presentation and at last follow-up.
Discussion
This report highlights a case of severe hypercalcaemia in
an infant with CAKUT, CKD stage II, and ultrasound
findings suggesting renal dysplasia. The sodium wasting
seen at admission is indicative of renal dysplasia. The ex-
tensive workup performed left PTHrP-related hypercal-
caemia as the most probable aetiology. The case was
interesting as hypercalcaemia is uncommon in infancy,
and PTHrP-associated hypercalcaemia without malig-
nancy or benign renal mass is rarely described. To the
best of our knowledge, there has only been one pub-
lished case report describing a similar patient [9],
although hypercalcaemia has been reported in as many
as 15% of patients with CAKUT [13]. Our case differed
from the 2 patients described by Srivastava et al., where
benign congenital mesobastic nephroma caused substan-
tial PTHrP elevations [8]. Our case is similar to that
described by Grob et al., who described an infant with
stage III chronic kidney failure secondary to multicystic
dysplastic kidney disease who presented with severe
hypercalcaemia, suppressed PTH, and elevated PTH-
related peptide at 3 months of life [9]. Malignancy was
also ruled out in that case and unlike our patient, the
patient was treated with bisphosphonates twice, resulting
in a successful though delayed response.
PTHrP is a pleiotropic factor with multiple physio-
logical functions in morphogenesis, cell proliferation,
differentiation, apoptosis, and calcium homeostasis. In
the kidney, PTHrP is abundantly expressed and upregu-
lated in various experimental nephropathies, showing
growth-modulatory and pro-inflammatory properties
[14]. Despite the widespread production of PTHrP in
the normal tissues of healthy individuals, the concentra-
tion of the protein is below the detectable limit of
current assays (<0.2 pmol/L in the N-terminal(1–86)-re-
gion-specific PTHrP radioassay) [15], suggesting that
PTHrP normally functions locally in an autocrine or para-
crine manner. PTHrP also has a proliferative effect on
both glomerular mesangial cells and tubular epithelial cells
[16]. Increases in the expression of PTHrP have been ob-
served in several experimental models of nephropathies,
suggesting that PTHrP upregulation is a common event
associated with the mechanism of renal injury and repair
[16]. Our case report suggests that hypercalcaemia may
result from the overproduction of PTHrP in patients with








Figure 3 Serum calcium concentrations from initial admission to last follow-up.
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Our case is important because hypercalcaemia in children
with CAKUT is relatively common and may be unrelated
to vitamin D therapy [13]. The low vitamin D level is actu-
ally consistent with the diagnosis, as a low level is protective
and often seen in patients with hyperparathyroidism or
(as in our case) PTHrP elevation. We acknowledge that
availability of PTHrP testing is limited and the several week
turn around time of several weeks is impractical for the
acute management. Our case may also suggest alternative
approaches to maintain normocalcaemia with hydration,
furosemide, and calcitonin. Alternatives would be beneficial
because bisphosphonate therapy is not well-established in
infants, may be associated with severe skeletal toxicity [17],
and could perhaps be reserved for calcitonin-resistant cases.
In Al-Kalbani’s series, 15 of 99 infants with renal dysplasia
had hypercalcaemia, and patients with obstructive uropa-
thy, as was true in our case, were most commonly affected
[13]. In Al-Kalbani’s series, the mean Schwartz eGFR was
57 mL/min/1.73 m2, similar to our patient, but but the
range was wide. Only 30% of the patients in that series had
an elevated PTH, while the others were similar to our pa-
tient [13]. More importantly, the mean duration of the
hypercalcaemia was 5.2 months in Al-Akalbani’s series [13],
which may significantly contribute to the substantial risk of
vascular calcifications, a potentially life limiting sequela rec-
ognized in children with CKD [18]. The use of intravenous
hydration, furosemide, and calcitonin allow for a rapid
normalization of hypercalcaemia [19], and the use of a low-
calcium diet alone may be advantageous in maintaining a
more long-term normocalcaemia over bisphosphonates.
Conclusions
We conclude that hypercalcaemia may result from the
overproduction of PTHrP in patients with CAKUT and
adequately suppressed PTH, and that hypercalcaemia
secondary to PTHrP in children with CAKUT, particu-
larly when they have an element of obstruction, may be
under-recognized. Investigations should include PTH,
and if this is adequately suppressed, measuring PTHrP
should be considered. Intravenous hydration, furosem-
ide, and calcitonin facilitate a rapid normalization of the
serum calcium, and normocalcaemia may be maintained
with CalciLo rather than with bisphosphonates.
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Table 1 Patient serum and urine parameters at presentation and last follow-up
Serum or urine parameter At presentation At last follow-up Age-appropriate reference interval
Serum creatinine 63 μmol/L 34 μmol/L <53 μmol/L
Cystatin C eGFR 51 mL/min/1.73 m2 89 mL/min/1.73 m2 >90 mL/min/1.73 m2
Serum calcium 4.98 mmol/L 2.67 mmol/L 2.24-2.74 mmol/L
Serum urea 13.7 mmol/L 6.1 mmol/L <8.0 mmol/L
Serum bicarbonate 15 mmol/L 21 mmol/L 22-29 mmol/L
Serum sodium 134 mmol/L 139 mmol/L 135-145 mmol/L
Fractional sodium excretion 20.06% n.d. N/A
Urine calcium 2.93 mmol/L 1.45 mmol/L N/A
Uca/cr ratio 9.8 mmol/mmol 0.822 mmol/mmol <1 at 6 months, <0.6 at 2 years
PTH 0.4 pmol/L 3.3 pmol/L 1.6-6.9 pmol/L
25-vitamin D 140 nmol/L 94 nmol/L 75-225 nmol/L
1,25 dihydroxy-vitamin D <10 pmol/L n.d. 39-193 pmol/L
Vitamin A 0.7 μmol/L n.d. 1.2-2.8 μmol/L
Alkaline phosphatase 206 U/L 296 U/L <449 U/L
PTHrP 3.8 pmol/L n.d. <2 pmol/L
Phosphate 0.83 mmol/L 1.83 mmol/L 1.3-2.6 mmol/L
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